Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors

被引：8

作者：

Oziel-Taieb, Sandrine ^{[1
]}

Zemmour, Christophe ^{[2
]}

Raoul, Jean-Luc ^{[3
]}

Mineur, Laurent ^{[4
]}

Poizat, Flora ^{[5
]}

Charrier, Nathalie ^{[6
]}

Piana, Gilles ^{[7
]}

Cavaglione, Gerard ^{[8
]}

Niccoli, Patricia ^{[1
]}

机构：

[1] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Med Oncol, Marseille, France

[2] Aix Marseille Univ, Inst Paoli Calmettes, Dept Clin Res & Invest, Biostat & Methodol Unit,INSERM,IRD,SESSTIM, Marseille, France

[3] Inst Cancerol Ouest, Dept Digest Oncol, Nantes, France

[4] St Catherine Inst, Gastro Intestinal & Liver Canc Unit, Avignon, France

[5] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Biopathol, Marseille, France

[6] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Nucl Med, Marseille, France

[7] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Radiol, Marseille, France

[8] Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 04期

关键词：

Chemotherapy; enteropancreatic neuroendocrine tumors; metastases; oxaliplatin;

D O I：

10.21873/anticanres.14977

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: FOLFOX (5-Fluorouracile and oxaliplatin) exhibits promising activity in advanced well-differentiated neuroendocrine tumors (NETs). This retrospective study aimed to analyze the outcome of metastatic enteropancreatic NETS patients treated with FOLFOX. Patients and Methods: We retrospectively identified patients treated with FOLFOX for NETs of enteropancreatic or unknown origin among those referred to our Regional Multidisciplinary Tumor Board. Results: Among 48 patients, most often pancreatic NETs (n=33, 68.8%), the median Ki67 index was 10%. The median number cycle of FOLFOX was 6 and median follow-up was 34.8 months. Disease control rate (DCR) was 83 3%. Median PFS and OS were 12.6 and 29.4 months respectively. Median chemotherapy break was 14.1 months. No significant difference was observed between PFS and the following criteria: Ki67 index, primary tumor site, alkaline phosphatase levels, primary tumor surgery and F-18-FDG PET positivity. Conclusion: FOLFOX exhibits a high DCR and a short duration of treatment with a relative long chemotherapy break in patients with metastatic enteropancreatic NETs.

引用

页码：2071 / 2078

页数：8

共 50 条

[41] The Efficacy of Chemotherapy in Patients with High-Grade Metastatic Colon Cancer [J].

Liu, Chia-Jen ;

Lin, Jen-Kou ;

Chen, Wei-Shone ;

Lin, Tzu-Chen ;

Yang, Shung-Haur ;

Jiang, Jeng-Kai ;

Chang, Shih-Ching ;

Lan, Yuan-Tzu ;

Yen, Chueh-Chuan ;

Tzeng, Cheng-Hwai ;

Wang, Hsei-Wei ;

Teng, Hao-Wei .

HEPATO-GASTROENTEROLOGY, 2011, 58 (110) :1495-1501

[42] Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer [J].

Suenaga, Mitsukuni ;

Mizunuma, Nobuyuki ;

Matsusaka, Satoshi ;

Shinozaki, Eiji ;

Ueno, Masashi ;

Yamaguchi, Toshiharu .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) :322-329

[43] Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors Case series [J].

Mueller, Christian ;

Kreissl, Michael C. ;

Klose, Silke ;

Krause, Andreas ;

Keitel, Verena ;

Venerito, Marino .

MEDICINE, 2022, 101 (04) :E28610

[44] Palliative chemotherapy for metastatic and locally advanced gastrointestinal tumors [J].

Dippold, W .

ZENTRALBLATT FUR CHIRURGIE, 1998, 123 (06) :722-724

[45] First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma [J].

Bongiovanni, Alberto ;

Riva, Nada ;

Ricci, Marianna ;

Liverani, Chiara ;

La Manna, Federico ;

De Vita, Alessandro ;

Foca, Flavia ;

Mercatali, Laura ;

Severi, Stefano ;

Amadori, Dino ;

Ibrahim, Toni .

ONCOTARGETS AND THERAPY, 2015, 8 :3613-3619

[46] Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience [J].

Gorbunova, V ;

Orel, N. ;

Kuzminov, A. ;

Emelianova, G. ;

Odintsova, A. ;

Polozkova, S. ;

Markovich, A. .

NEUROENDOCRINOLOGY, 2016, 103 :67-67

[47] Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities [J].

Shaheen, Shagufta ;

Moradi, Farshad ;

Gamino, Gerardo ;

Kunz, Pamela L. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (04)

[48] Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction [J].

Elsoueidi, Raymond ;

Craig, Jessica ;

Mourad, Hesham ;

Richa, Elie M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (02) :155-160

[49] Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective [J].

Phan, Alexandria T. .

CANCER TREATMENT REVIEWS, 2013, 39 (01) :3-9

[50] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer [J].

Ozaslan, Ersin ;

Topaloglu, Ulas Serkan ;

Inanc, Mevlude ;

Erdem, Umut Gokmen ;

Demir, Hacer ;

Arpaci, Erkan ;

Seker, Mehmet Metin ;

Karaaga, Mustafa ;

Kiziltepe, Melih ;

Eker, Baki ;

Ozkan, Metin .

JOURNAL OF BUON, 2017, 22 (04) :863-868

← 1 2 3 4 5 →